Pressure BioSciences Inc. PBIO Archives - Page 20 of 22

WednesdayMay 02, 2018 10:44 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) CEO to Host Webinar on May 2

Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) this morning announced that Richard T. Schumacher, the company’s president and CEO, will be hosting a webinar update and live Q&A session for investors today at 3:00 pm EDT. Per the update, the webinar will include discussions on enhancements made to products in PBIO’s core Research Products & Services business segment, the company’s new field salesforce, its acquisition of the assets of BaroFold Corporation and the issuance of patents related to the company’s cutting-edge Ultra Shear Technology (“UST”) platform. Schumacher is also expected to offer a brief outlook for the 2018…

FridayApr 13, 2018 11:39 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Sees 2018 as Year of Growth for BaroFold, Ultra Shear Technology Programs

Pressure BioSciences (OTCQB: PBIO) recently announced newly-issued patents in Ultra Shear Technology (“UST”) that address broad markets for stable, water-soluble nanoemulsions, including cannabinoids. An article further discussing the company reads: “With the BaroFold acquisition and the new developments in Ultra Shear Technology (including two issued patents), Pressure BioSciences now has three distinct working groups — its research products and services unit, its biologics contract research services unit and its Ultra Shear Technology (UST) development unit. … The UST platform incorporates a novel technique based on the use of intense shear forces generated from ultra-high pressure valve discharge, which the company…

TuesdayApr 10, 2018 12:27 pm

Pressure BioSciences Inc.’s (PBIO) New Products and Enhanced Sales Capabilities Drive Plans for Banner 2018

Record product sales growth reported for fourth quarter and full year 2017 Company has over 300 of its ultra-high pressure instruments in research labs worldwide 2017 revenue exceeded $2.2 million with just one field sales rep; company’s field sales force expanded to five with recent hires December 2017 acquisition of high pressure IP allows company to enter the biologics contract research services sector Newly-issued patents in Ultra Shear Technology (UST) address broad markets for stable, water-soluble nanoemulsions, including cannabinoids As scientific researchers who work with cellular material seek to uncover new potential for creating vaccines and drugs, counteracting harmful chemicals…

TuesdayApr 03, 2018 12:33 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces FY2017 Financial Results

Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2017. The company also provided a business update and offered limited guidance for FY2018. Among the highlights, PBIO reported $502,708 in total revenue for the three-month period, marking a year-over-year increase of 20 percent that it attributed primarily to double-digit growth in its products and services. The company recorded similarly strong results for the 12-month period, reporting $2.24 million in annual revenue for a year-over-year increase of 13 percent. “This past year was filled with a…

ThursdayDec 27, 2007 8:14 am

Pressure BioSciences, Inc. (PBIO) Shares Rebound Over 7%

After an inexplicable sell off, PBIO shares rebounded strong. The falling share price has been attributed by many to have been caused by confusion linking Pressure BioSciences, Inc. and Panacos Pharmaceuticals Inc. which neared its 52 week low after disappointing results. Previously Pressure BioSciences had a position in Panacos Pharmaceuticals, but sold off all its interest over six months ago. The Company has attracted the attention of several analysts and has been awarded 12-month price targets as high as $10 – a near double from the current price. The most recent report published by Dutton Associates on December 18 detailed that…

FridayDec 21, 2007 9:00 am

Pressure Biosciences, Inc. (PBIO) Posts Recognized Revenue Increases

Pressure Biosciences (NASDAQ: PBIO) recently announced its September 2007 quarter highlights for the period ended September 30, 2007. The company posted revenue of $138,052, as compared to $92,211 for the same period in 2006. Revenue from the sale of the company’s Pressure Cycling Technology (PCT) sample preparation products and services was $106,787; up from $92,211 from the same period last year. The increase in revenue is attributed to increased installations of PCTs, which rose to eight installations in the 2007 quarter, as compared to three for the same period of 2006. The company also sold two Barocycler NEP3229s, four Barocycler…

FridayDec 21, 2007 5:51 am

Pressure BioSciences, Inc. (PBIO) has Finances In Order and Anticipating a Successful 2008

Pressure BioSciences ended the third quarter of this year with $6.0 million in cash. The use of cash by operations matched up with expectations that the company’s cash position could finance operations into the last part of 2008. In March, the company sent a purchase order to Source Scientific, LLC to purchase 20 Barocycler NEP3229 units and 9 Barocycler NEP2320 units. The finished products will remain at Source Scientific until needed, then be shipped directly to Pressure BioSciences’ customers. The company anticipates that all of these units will be completely fabricated and available for sale early next year. Because Pressure…

WednesdayDec 19, 2007 7:35 pm

Pressure BioSciences, Inc. (PBIO) is Making the Right Steps as Scientists and Research Firms Around the Nation Take Notice

Pressure BioSciences has continued to add research and development personnel to its staff to expand the number, as well as the scope, of R&D projects underway. The Company anticipates that its increased investments in R&D will complement its commercialization efforts by encouraging the continued publication of application notes in areas currently using PCT technology and creating new inventions that rely on its PCT technology. The Company recently announced that a study focused on the discovery and identification of potential biomarkers of colon cancer was presented at the Annual Scientific Meeting of the American College of Gastroenterology (ACG). The study specifically…

WednesdayDec 19, 2007 6:52 am

Pressure BioSciences, Inc. (PBIO) Making Substantial Progress Following Strategic Business Plan

Pressure BioSciences has been committed to accomplishing its corporate goals for this year and has experienced success in many areas. The Company brought seven full-time sales directors on board to achieve better regional coverage, which exceeds the initial goal of five. The new sales team has previous experience selling either sample preparation or life sciences capital equipment and many have worked in laboratories. The Company is currently training the new hires and anticipates the team to be fully operational early next year. The company has also succeeded in increasing sales as a total of 10 Barocycler NEP3229 were commissioned. Four…

WednesdayDec 19, 2007 5:50 am

Pressure BioSciences, Inc. (PBIO) Products Aid in the Study of Diabetes, Cancer, ALS, Heart Disease and Other Disorders

Barocycler NEP3229: The Barocycler NEP3229 is a high-pressure laboratory instrument that is designed to fit on a bench top, inside a biological safety cabinet, or on the shelf of a cold room while having the power to generate up to 35,000 psi. The instrument has the ability to process up to three samples at the same time by utilizing specially designed PULSE Tubes. An external chiller hook-up, automatic fill and dispense valves, and an integrated microprocessor with programmable logic controller is included. Barocycler NEP2320: The Barocycler NEP2320 is a more compact alternative of the Barocycler NEP3229. It has the same…

Site Search

Company Search

Tag: Pressure BioSciences Inc. PBIO